Furthermore, existing anti-obesity drugs (such as GLP-1 receptor agonists) or lifestyle interventions (such as exercise, dietary regulation) could be considered in combination to assess the synergistic effect. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.